Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations | Zendy

Jonathan D. Cogen | Zendy; Anna Faino | Zendy; Frankline Onchiri | Zendy; Lucas R. Hoffman | Zendy; Matthew P. Kronman | Zendy; David P. Nichols | Zendy; Margaret Rosenfeld | Zendy; Ronald L. Gibson | Zendy

Open Access

Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations

Author(s) -

Jonathan D. Cogen,

Anna Faino,

Frankline Onchiri,

Lucas R. Hoffman,

Matthew P. Kronman,

David P. Nichols,

Margaret Rosenfeld,

Ronald L. Gibson

Publication year - 2021

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciab525

Subject(s) - medicine , cystic fibrosis , intravenous antibiotics , antibiotics , intensive care medicine , microbiology and biotechnology , biology

Pulmonary exacerbations (PEx) in people with cystic fibrosis (PwCF) are associated with significant morbidity. While standard PEx treatment for PwCF with Pseudomonas aeruginosa infection includes two IV antipseudomonal antibiotics, little evidence exists to recommend this approach. This study aimed to compare clinical outcomes of single versus double antipseudomonal antibiotic use for PEx treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research